Imatinib Completed Phase 1 Trials for Neoplasms, Malignant / Unspecified Adult Solid Tumor, Protocol Specific Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00026169Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure